Cholinergic pathways and cognition in patients with schizophrenia: A pilot study

Schizophrenia Research

Volumn 139, Issue 1-3, 2012, Pages 46-52

  Rajji, Tarek K ^a,b   Chow, Tiffany W ^a,b,c,d   Voineskos, Aristotle N ^a,b   Links, Kira A ^c   Miranda, Dielle ^a,b   Mamo, David C ^a,b   Ismail, Zahinoor ^a,b   Pollock, Bruce G ^a,b   Mulsant, Benoit H ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROTMAN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cholinergic; Cognition; Executive function; Schizophrenia; White matter hyperintensities

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN DYSFUNCTION; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLINERGIC AGENTS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEURAL PATHWAYS; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84863777243     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.006     Document Type: Article

References (60)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. Text Revision 2000, American Psychiatric Press, Washington, D.C. Fourth Edition.
2. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., Silva A.J. Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6(1):51-58.
3. Behl P., Bocti C., Swartz R.H., Gao F., Sahlas D.J., Lanctot K.L., Streiner D.L., Black S.E. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch. Neurol. 2007, 64(2):266-272.
4. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal-cortex of schizophrenics. Arch. Gen. Psychiatry 1979, 36(9):927-934.
5. Bocti C., Swartz R.H., Gao F.Q., Sahlas D.J., Behl P., Black S.E. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 2005, 36(10):2126-2131.
6. Bohnen N.I., Muller M., Kotagal V., Koeppe R.A., Kilbourn M.A., Albin R.L., Frey K.A. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010, 133:1747-1754.
7. Chew M.L., Mulsant B.H., Pollock B.G., Lehman M.E., Greenspan A., Mahmoud R.A., Kirshner M.A., Sorisio D.A., Bies R.R., Gharabawi G. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 2008, 56(7):1333-1341.
8. Cohen J.D., Servan-Schreiber D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr. Bull. 1993, 19(1):85-104.
9. Cooper J.A., Sagar H.J., Doherty S.M., Jordan N., Tidswell P., Sullivan E.V. Different effects of dopaminergic and anticholinergic therapies on cognitiive and motor function in Parkinsons-disease - a follow-up-study of untreated patients. Brain 1992, 115:1701-1725.
10. Crook J.M., Dean B., Pavey G., Copolov D. The binding of [H-3]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci. 1999, 64(19):1761-1771.
11. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 2000, 48(5):381-388.
12. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 2001, 158(6):918-925.
13. Daskalakis Z.J., George T.P. Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clin. Pharmacol. Ther. 2009, 86(4):442-446.
14. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M(1) receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol. Psychiatry 1996, 1(1):54-58.
15. Deng C., Huang X.F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J. Neurosci. Res. 2005, 81(6):883-890.
16. Dubois B., Pillon B., Lhermitte F., Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinsons-disease. Ann. Neurol. 1990, 28(2):117-121.
17. First M.B. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition 2002, Biometrics Research, New York State Psychiatric Institute, New York.
18. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state - practical method for grading cognitive state of patients for clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
19. Freedman R., Coon H., MylesWorsley M., OrrUrtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(2):587-592.
20. Goldman-Rakic P.S. Topography of cognition: Parallel distributed networks in primate association cortex. Ann. Rev. Neurosci. 1988, 11:137-156.
21. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
22. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72(1):41-51.
23. Hasselmo M.E., Bower J.M. Cholinergic suppression specific to intrinsinc not afferent fiber synapses in rat piriform (olfactory) cortex. J. Neurophysiol. 1992, 67(5):1222-1229.
24. Hasselmo M.E., Giocomo L.M. Cholinergic modulation of cortical function. J. Mol. Neurosci. 2006, 30(1-2):133-135.
25. Hasselmo M.E., Anderson B.P., Bower J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol. 1992, 67(5):1230-1246.
26. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
27. Holt D.J., Bachus S.E., Hyde T.M., Wittie M., Herman M.M., Vangel M., Saper C.B., Kleinman J.E. Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biol. Psychiatry 2005, 58(5):408-416.
28. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
29. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23(1):99-110.
30. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9(12):1200-1213.
31. Lee M.G., Hassani O.K., Alonso A., Jones B.E. Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep. J. Neurosci. 2005, 25(17):4365-4369.
32. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
33. MacDonald A.W., Cohen J.D., Stenger V.A., Carter C.S. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000, 288(5472):1835-1838.
34. Maixner S., Tandon R., Eiser A., Taylor S., DeQuardo J.R., Shipley J. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension. Am. J. Psychiatry 1998, 155(11):1600-1602.
35. McBride T., Moberg P.J., Arnold S.E., Mozley L.H., Mahr R.N., Gibney M., Kumar A., Gur R.E. Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophr. Res. 2002, 55(3):217-227.
36. McCormick D.A., Prince D.A. 2 types of muscarinic response to acetylcholine in mammalian cortical-neurons. Proc. Natl. Acad. Sci. U. S. A. 1985, 82(18):6344-6348.
37. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., Mulsant B., Reynolds C.F. Rating chronic medical illness burden in geropsychiatric practice and research - application of the cumulative illness rating-scale. Psychiatry Res. 1992, 41(3):237-248.
38. Mulsant B.H., Pollock B.G., Kirshner M., Shen C.Y., Dodge H., Ganguli M. Serum anticholinergic activity in a community-based sample of older adults - relationship with cognitive performance. Arch. Gen. Psychiatry 2003, 60(2):198-203.
39. Myers C.S., Robles O., Kakoyannis A.N., Sherr J.D., Avila M.T., Blaxton T.A., Thaker G.K. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology 2004, 174(3):334-340.
40. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72(1):29-39.
41. O'Keane V., Abel K., Murray R.M. Growth-hormone responses to pyridostigmine in schizophrenia - evidence for cholinergic dysfunction. Biol. Psychiatry 1994, 36(9):582-588.
42. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52(12):998-1007.
43. Pappas B.A., Bayley P.J., Bui B.K., Hansen L.A., Thal L.J. Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol. Aging 2000, 21(1):11-17.
44. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Egan M.F., Weinberger D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 2003, 28(8):1531-1537.
45. Raedler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 2007, 12(3):232-246.
46. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20(3):310-319.
47. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery 1993, Neuropsychology Press, Tucson.
48. Riemann D., Hohagen F., Krieger S., Gann H., Muller W.E., Olbrich R., Wark H.J., Bohus M., Low H., Berger M. Cholinergic REM induction test - muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J. Psychiatr. Res. 1994, 28(3):195-210.
49. Royall D.R., Mahurin R.K., Gray K.F. Bedside assessment of executive cognitive impairment - the executive interview. J. Am. Geriatr. Soc. 1992, 40(12):1221-1226.
50. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia - involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62(6):649-659.
51. Sarter M., Parikh V., Howe W.M. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat. Rev. Neurosci. 2009, 10(5):383-390.
52. Scarr E., Sundrarn S., Keriakous D., Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry 2007, 61(10):1161-1170.
53. Scarr E., Cowie T.F., Kanellakis S., Sundram S., Pantelis C., Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry 2009, 14(11):1017-1023.
54. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121:2249-2257.
55. Steriade M., Amzica F., Nunez A. Cholinergic and noradrenergic modulation of the slow (approximate-to-0.3Hz) oscillation in neocortical cells. J. Neurophysiol. 1993, 70(4):1385-1400.
56. Swartz R.H., Sahlas D.J., Black S.E. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter?. J. Stroke Cerebrovasc. Dis. 2003, 12(1):29-36.
57. Uchida H., Rajji T.K., Mulsant B.H., Kapur S., Pollock B.G., Graff-Guerrero A., Menon M., Mamo D.C. D-2 receptor blockade by attention deficits in risperidone correlates with late-life schizophrenia. J. Clin. Psychopharmacol. 2009, 29(6):571-575.
58. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 2009, 166(9):1055-1062.
59. Wilson F.A.W., Rolls E.T. Neuronal responses related to reinforcement in the primate basal forebrain. Brain Res. 1990, 509(2):213-231.
60. Wilson F.A.W., Rolls E.T. Neuronal responses related to the novelty and familiarity of visual-stimuli in the substantia innominata, diagonal band of Broca and periventricular region of the primate basal forebrain. Exp. Brain Res. 1990, 80(1):104-120.